Assistant, Associate or Full Professor- Clinical X Series (Hematology/Oncology)
Open October 20, 2022 through Friday, Oct 20, 2023 at 11:59pm (Pacific Time)
The Division of Hematology/Oncology in the Department of Medicine is recruiting for clinical investigator faculty members at the level of Assistant Professor or above, in the Clinical Professor Series, (Clinical X Series). The Clinical X series is reserved for faculty with exceptional clinical acumen, educational expertise, clinical investigational skills, and/or scholarly productivity. Faculty in these positions are expected to be productive in the scholarly activities matching one or more of the Institution’s missions: Discover, Teach, Heal.
Minimum requirements: MD, MD/PhD or equivalent degree, Board certification or eligibility in adult Hematology and/or Medical Oncology, and eligibility to obtain an active medical practice license in the State of California. Candidates are expected to leading and conducting clinical/translational research and be leaders in specific sub-disciplines of Hematology Oncology including but are not limited to: breast neoplasms, gastrointestinal malignancies inclusive of hepatobiliary neoplasms, genitourinary malignancies, gynecologic oncology (non-surgical), head/neck malignancies, melanoma/skin malignancies, thoracic malignancies, malignant hematology (AML, ALL, CML, CLL, Hematopoietic Stem Cell Transplant, lymphomas, myeloma), benign hematology, and supportive/palliative oncology. Interested candidates are requested to identity their specialty area(s) of interest and expertise in their application statements. It is expected that clinical investigator faculty will have a substantial amount of effort (≧ 40%) spent on non-clinical activities.
UC Irvine is home to one of 53 NCI-designated comprehensive cancer centers and one of only 23 institutions also holding a Clinical Translational Science Award. Powered by all of the Schools within the University of California, Irvine, UCI Health is home to the only university-based academic Hematology Oncology practice in Orange County. UCI Health is building a 575,000 sq ft Irvine medical campus that will double the outpatient capacity for cancer care and house a 144 bed specialty hospital. The former will come on line in late 2023 and the latter in late 2025.
MD, MD/PhD or equivalent degree, Board certification or eligibility in adult Hematology and/or Medical Oncology, and eligibility to obtain an active medical practice license in the State of California. Candidates are expected to lead and conduct clinical and/or translational research within a specific area of focus. Areas of specialty include but are not limited to – malignant hematology (AML, ALL, CML, CLL, Stem Cell Transplant, lymphomas, myeloma), benign hematology, breast neoplasms, gastrointestinal malignancies inclusive of hepatobiliary neoplasms, genitourinary malignancies, gynecologic oncology (non-surgical), head/neck malignancies, melanoma/skin malignancies, sarcomas and thoracic malignancies
Curriculum Vitae - Your most recently updated C.V.
Cover Letter (Optional)
Statement of Research
Teaching Statement - See our guidance for writing a reflective teaching statement.
Inclusive Excellence Activities Statement - Statement addressing how past and/or potential contributions to inclusive excellence will advance UCI's Commitment to Inclusive Excellence. See our guidance for writing an inclusive excellence activities statement.
Misc / Additional (Optional)
- 5-12 required (contact information only)
The University of California, Irvine is an Equal Opportunity/Affirmative Action Employer advancing inclusive excellence. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, protected veteran status, or other protected categories covered by the UC nondiscrimination policy.
As a condition of employment, you will be required to comply with the University of California Policy on Vaccination Programs – With Updated Interim Amendments. All Covered Individuals under the policy must provide proof of receiving the COVID-19 Vaccine Primary Series or, if applicable, submit a request for Exception (based on Medical Exemption, Disability, Religious Objection, and/or Deferral based on pregnancy or recent COVID-19 diagnosis and/or treatment) no later than the applicable deadline. All Covered Individuals must also provide proof of receiving the most recent CDC-recommended COVID-19 booster or properly decline such booster no later than the applicable deadline. New University of California employees should refer to Exhibit 2, Section II.C. of the SARS-CoV-2 (COVID-19) Vaccination Program Attachment for applicable deadlines. All Covered Individuals must also provide proof of being up-to-date on seasonal influenza vaccination or properly decline such vaccination no later than the applicable deadline. Please refer to the Seasonal Influenza Vaccination Program Attachment. (Capitalized terms in this paragraph are defined in the policy.) Federal, state, or local public health directives may impose additional requirements.